Martin Alpert, MD
Family Medicine · Santa Monica, CANPI 1033150123
Payments from drug & device makers
Across 294 payments — averaging $22.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Amgen$893
- Bausch Health US, LLC$445
- AstraZeneca$324
- GSK$162
- Lilly USA, LLC$157
- plus $1K from 19 others
What the payments were for
- Food & beverage$6,496100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 155 | $3,490 |
| Amgen | 41 | $893 |
| Bausch Health US, LLC | 22 | $445 |
| AstraZeneca | 14 | $324 |
| GSK | 8 | $162 |
| Lilly USA, LLC | 7 | $157 |
| Almatica Pharma LLC | 7 | $147 |
| E.r. Squibb & Sons, L.L.C. | 4 | $103 |
| Novartis | 5 | $102 |
| Pfizer | 3 | $94 |
| Novo Nordisk | 4 | $92 |
| Otsuka America Pharmaceutical, Inc. | 3 | $84 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $79 |
| Sage Therapeutics, LLC | 2 | $54 |
| Scilex Pharmaceuticals Inc. | 2 | $38 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Azurity Pharmaceuticals, Inc. | 2 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Gilead | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Harmony Biosciences LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$265
How this compares
$6,496 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 38 | $43,044 |
| EliquisApixaban | 15 | $16,867 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $11,439 |
| Rosuvastatin Calcium | 115 | $2,351 |
| ValacyclovirValacyclovir Hcl | 30 | $1,810 |
| Ezetimibe | 48 | $1,288 |
| SynthroidLevothyroxine Sodium | 12 | $1,248 |
| Atorvastatin Calcium | 83 | $1,120 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 11 | $923 |
| Telmisartan | 39 | $900 |
| Doxycycline Hyclate | 24 | $894 |
| Pantoprazole Sodium | 47 | $869 |
| Metformin Hcl ErMetformin Hcl | 58 | $537 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 18 | $505 |
| Famotidine | 40 | $469 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $157 | $43,04438 claims |
| PfizerEliquis | $94 | $16,86715 claims |
| AbbVieSynthroid | $3,490 | $1,24812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Santa Monica
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.